Glow discharge plasma deposition (GDPD) technique for the local controlled delivery of hirudin from biomaterials

Characteristics of polyurethane-based sustained release membranes for drug delivery

This paper is focused on the preparation and physicochemical characterization of two poly(ester ether urethane)s with rifampicin in their matrix and different molar concentrations of urethane groups. The polyurethanes with rifampicin were processed as asymmetrical microporous membranes by a phase inversion method and characterized by attenuated total reflection — Fourier transform infrared (ATR-FTIR) spectroscopy and differential scanning calorimetry (DSC). The influence of the surface morphology in the release of drug compounds was analyzed by scanning electron microscopy (SEM), atomic force microscopy (AFM), contact angle, and water uptake. The release of rifampicin depends on the molar concentration of urethane groups and also on the surface morphology of the polyurethane membranes. The antibacterial activity was evaluated with S. Epidermidis RP 62 A and P. Aeruginosa ATCC 1544. Finally, the biocompatibility of the polyurethane membranes was studied with human dermal fibroblasts (HDF) to evaluate the potential biomedical applications.

The catastrophe revisited: blood compatibility in the 21st Century

The biomaterials community has been unable to accurately assign the term "blood compatible" to a biomaterial in spite of 50 years of intensive research on the subject. There is no clear consensus as to which materials are "blood compatible." There are no standardized methods to assess blood compatibility. Since we use millions of devices in contact with blood each year, it is imperative we give serious thought to this intellectual catastrophe. In this perspective, I consider five hypotheses as to why progress has been slow in evolving a clear understanding of blood compatibility: Hypothesis 1-It is impossible to make a blood compatible material. Hypothesis 2-We do not understand the biology behind blood compatibility. Hypothesis 3-We do not understand how to test for or evaluate blood compatibility. Hypothesis 4-Certain materials of natural origin seem to show better blood compatibility but we do not know how to exploit this concept. Hypothesis 5-We now have better blood compatible materials but the regulatory and economic climate prevent adoption in clinical practice.

The effect of pore formers on the controlled release of cefadroxil from a polyurethane matrix

The effect of various pore formers on the controlled release of an antibacterial agent from a polymeric device was examined in order to develop a novel biomaterial that prevents bacterial adhesion and growth on its surface. Cefadroxil was chosen as the model antibiotic and was incorporated into a polyurethane matrix by the solvent-casting method. Polyethylene glycol (PEG) 1450, D-mannitol, or bovine serum albumin (BSA) was used as a pore former. The amount of cefadroxil released from various formulations at 37 degrees C was measured by HPLC. The morphological change of matrices before and after release studies was investigated by scanning electron microscopy (SEM). The duration of antimicrobial activities of matrices against Escherichia coli and Bacillus subtilis was evaluated by measuring the diameters of the inhibition zone. Changing the weight fraction and particle size of the pore formers/drug mixtures could control the release of cefadroxil from the matrix. The release rate of cefadroxil increased as the loading dose of the pore former increased (15<20<25%). Cefadroxil released from these devices exhibited antibacterial activity for 5-6 days. These results imply that an antibiotic-loaded polymeric device that could prevent bacterial infection on its surface can be formulated using appropriate pore formers.

Design of infection-resistant antibiotic-releasing polymers. II. Controlled release of antibiotics through a plasma-deposited thin film barrier

In the first paper in this series, we described the methods to synthesize an antibacterial polyurethane (PU) incorporating ciprofloxacin as the releasable antibiotic and poly(ethylene glycol) as the pore-forming agent. Here, we report that a thin, RF-plasma-deposited, n-butyl methacrylate (BMA) overlayer on this drug-loaded PU can act as a rate-limiting barrier to achieve a constant, sustained release of ciprofloxacin. Deposition power and deposition time during the coating process were optimized to give an appropriate crosslinked coating barrier that yielded desirable release rates, above the minimum required killing rate, N(kill). Electron spectroscopy for chemical analysis (ESCA), also known as X-ray photoelectron spectroscopy (XPS), was used to characterize the coating, and its crosslinking degree was indirectly related to the C/O ratio. Increasing either deposition power (10-60 W) or duration (5-25 min) resulted in increased C/O ratios and decreased ciprofloxacin release rates. The correlation between increased C/O ratios and reduced release rates is believed to be due to the increased crosslinking, increased hydrophobicity and increased thickness of the coating. The optimal plasma conditions to attain an appropriate crosslinked plasma-deposited film (PDF) required argon etching, pre-treatment of the matrices with an 80W-BMA plasma for 1 min, followed by immediate BMA plasma deposition at 40 W and 150 mT for 20 min. By using these plasma deposition protocols, we eliminated the initial burst effect, significantly reduced the release rates, and closely approached the zero order release kinetics for at least five days. In this study, we also showed that ESCA could be used as a powerful tool to explain the release behavior of molecules through the plasma-deposited films (PDFs).

Design of infection-resistant antibiotic-releasing polymers: I. Fabrication and formulation

Biomaterials-related infections are often observed with prosthetic implants and in many cases result in the failure of the devices. To design a biomedically useful polymer that is intrinsically infection-resistant, we have developed a ciprofloxacin-loaded polyurethane (PU) matrix that releases antibiotic locally at the implant surface, thereby minimizing bacterial accumulation. We report here the methods of fabrication and formulation for making such antibiotic-loaded devices, as well as evidence of their bactericidal properties. Specifically, various pore-forming agents and drug loadings were examined. An optimum formulation consisting of BIOSPAN PU, poly(ethylene glycol) and ciprofloxacin offered the longest effective period of sustained release (5 days). The bactericidal efficacy of the released ciprofloxacin against Pseudomonas aeruginosa (PA) was four times that of the control PU without antibiotics. This bactericidal efficiency was due to an increase in the PA detachment from the surface. These observations suggested that the released ciprofloxacin was biologically active in preventing the bacteria from permanently adhering to the substratum, and thus decreasing the possibility of biofilm-related infection.